IGA NEPHROPATHY

This study tested a new drug called BION-1301 in 103 healthy volunteers and adults with IgA nephropathy, a kidney disease. The main goal was to check the drug's safety and how the body processes it. Researchers measured side effects, blood pressure, and kidney function over time.

This study tested a new drug called XH-S003 in 25 adults with IgA nephropathy, a kidney disease. The goal was to see if the drug is safe and can reduce protein in the urine, a sign of kidney damage, after 90 days. Participants had to have a kidney biopsy confirming the disease. T…

This study tested whether a probiotic supplement could change gut bacteria and reduce harmful antibodies that damage kidneys in IgA nephropathy. 18 adults with the disease took probiotics for 3 months. Researchers measured changes in antibody levels and kidney function to see if …

This completed early-stage trial tested an experimental drug called ARO-C3 in 62 healthy volunteers and patients with two types of kidney disease (C3 glomerulopathy and IgA nephropathy). The drug is designed to calm an overactive part of the immune system that can damage the kidn…

This early-stage trial tested a drug called ARO-CFB in 49 healthy volunteers and people with IgA nephropathy, a kidney disease where the immune system damages the kidneys. The main goal was to check safety and how the drug moves through the body. Participants received either one …

This early-phase trial tested the safety of a new drug called VIS649 in 51 healthy volunteers. VIS649 is an antibody that blocks a protein called APRIL, which is thought to play a role in IgA nephropathy, a kidney disease. The study gave single doses of the drug or a placebo and …

This study tested a new drug called HR19042 in 316 adults with IgA nephropathy, a kidney disease. The goal was to see if the drug can reduce protein in the urine, a sign of kidney damage, and find the best dose. Participants took either the drug or a placebo for a set period, and…

This study tested whether adding the drug atrasentan to standard care (including SGLT2 inhibitors) can reduce protein in the urine of people with IgA nephropathy, a kidney disease. 54 adults with biopsy-confirmed IgA nephropathy participated. The main goal was to see if atrasenta…

This phase 3 trial tested iptacopan (LNP023) in 518 adults with IgA nephropathy, a kidney disease that can lead to kidney failure. Participants received either the drug or a placebo, on top of standard care. The goal was to see if iptacopan reduces protein in the urine and slows …

This study tested whether adding early steroids or SGLT2 inhibitors to standard blood pressure medication can better protect kidney function in people with IgA nephropathy who have severe kidney damage. 62 adults with active disease were randomly assigned to receive either the co…

This study follows 211 people with IgA nephropathy who previously took a 6-9 month course of the steroid methylprednisolone in the TESTING trial. Researchers want to see if the steroid helped prevent end-stage kidney disease (needing dialysis or a transplant) over the long term. …

This completed study looked at why people with IgA nephropathy (a kidney disease) often experience memory and attention problems. Researchers used powerful 7-Tesla MRI scanners to examine the brains of 100 patients and 100 healthy volunteers, along with analyzing their gut bacter…